{
  "abstract": "Chronic obstructive pulmonary disease (COPD) remains a major global health challenge and is characterised by persistent respiratory symptoms and progressive airflow obstruction. 1 It has been traditionally managed as a neutrophilic disease; however, it is now established that about 40% of patients exhibit type 2 inflammation involving elevated blood eosinophil counts.2 3",
  "authors": [
    {
      "affiliations": [],
      "name": "BMJ Publishing Group Ltd"
    }
  ],
  "title": "Dupilumab in chronic obstructive pulmonary disease",
  "uid": "5d93619f-2f5d-5d4d-a1a3-3b1411ea405f"
}